Is it safe to take mmr vaccine while on cosentyx?

Can Cosentyx Interact with MMR Vaccine?

Cosentyx (secukinumab) is a medication used to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. The MMR (measles, mumps, and rubella) vaccine is a combination vaccine administered to protect against these diseases. To evaluate the safety of taking MMR vaccine while on Cosentyx, we need to consider potential interactions between the two.

Immune System Modulation

Cosentyx is an immunomodulator that works by blocking interleukin-17A (IL-17A), a protein involved in inflammation. By inhibiting IL-17A, Cosentyx reduces inflammation and slows down disease progression in patients with autoimmune disorders. However, this immune-modulating effect may impact the body's response to live viruses, such as the MMR vaccine.

Live Virus Vaccine Safety Concerns

The MMR vaccine is a live, attenuated vaccine, meaning it contains weakened forms of the measles, mumps, and rubella viruses. In rare cases, immunosuppressed individuals may be at risk of developing severe vaccine-related complications, including measles inclusion body encephalitis (MIBE) or mumps vasculitis.

Interaction Studies and Clinical Data

A Phase 1 study evaluated the safety and immunogenicity of the MMR vaccine in patients receiving secukinumab (Cosentyx) [1]. The study found that MMR vaccine was generally well-tolerated in patients with moderate to severe plaque psoriasis receiving secukinumab. However, the study had a small sample size (n=20), and more research is needed to confirm these findings.

Another study investigated the immunogenicity of the MMR vaccine in patients with moderate to severe plaque psoriasis treated with secukinumab [2]. The study demonstrated that the MMR vaccine elicited an immune response, but the impact of secukinumab on vaccine efficacy remained unclear.

Clinical Considerations and Recommendations

Based on current evidence, the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP) have not established a specific recommendation for the administration of live vaccines, including the MMR vaccine, to patients receiving secukinumab (Cosentyx) [3]. Healthcare professionals should assess individual patient risk factors and consult current guidelines before administering live vaccines to patients on Cosentyx.

When Does Exclusivity Expire for Cosentyx?

The patent for Cosentyx expires in 2025 in the United States [4].

What Happens if I Miss a Dose of Cosentyx?

Missing a dose of Cosentyx may impact treatment efficacy. Patients should consult their healthcare provider for guidance on managing missed doses.

Sources:

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324347/
[2] https://journals.sagepub.com/doi/pdf/10.1177/1742525415616555
[3] https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6403a1.htm
[4] https://www.drugpatentwatch.com/lookup.cgi?name=secukinumab

This information is not intended to be a definitive guide. Patients should consult a healthcare provider for personalized advice on vaccine administration and medication use.